For Immediate Release
Chicago, IL – January 11, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Coca-Cola Company (
KO Quick Quote KO - Free Report) , Merck & Co., Inc. ( MRK Quick Quote MRK - Free Report) , Royal Dutch Shell plc ( RDS.A Quick Quote RDS.A - Free Report) , Gilead Sciences, Inc. ( GILD Quick Quote GILD - Free Report) and FedEx Corporation ( FDX Quick Quote FDX - Free Report) . Here are highlights from Friday’s Analyst Blog: Top Analyst Reports for Coca-Cola, Merck & Royal Dutch Shell
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Coca-Cola, Merck and Royal Dutch Shell. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
all of today's research reports here >>> Coca-Cola shares have underperformed the Zacks Soft Drinks Beverages industry over the past year (-9.7% vs. -1.1%) reflecting the impact of lost sales due to restaurant closures. The Zacks analyst believes that Coca-Cola has been witnessing a surge in e-commerce with the growth rate of the channel doubling in many countries on the back of a shift in consumer behavior due to the coronavirus pandemic.
Although the earnings and sales declined on a year over year basis, the company's third-quarter 2020 revenues and volume reflected improved trends from the second quarter. It is poised to gain from the streamlining of portfolio and accelerating investments to expand digital presence due to shift in consumer preference.
However, continued pressures in the away-from-home channel, which account for nearly half of its revenues, hurt revenue growth. It also lost global value share in NARTD beverages on negative channel mix.
) read the full research report on Coca-Cola here >>>
Merck have gained +9.5% in the last six months against the Zacks Large Cap Pharmaceuticals industry's gain of +5.6%. The Zacks analyst believes that drugs like Keytruda, Lynparza and Bridion have been driving sales.
Keytruda sales are gaining from continued uptake in lung cancer and increasing usage in other cancer indications. Animal health and vaccine products remain core growth drivers. The potential separation into two companies makes strategic sense as the remaining Merck should be able to achieve higher profits than the combined company.
However, generic competition for several drugs and rising competitive pressure, mainly on the diabetes franchise will continue to be overhangs on the top line. Sales of some key products like Gardasil 9 vaccine are being hurt due to COVID-19 related business disruption.
) read the full research report on Merck here >>> Royal Dutch Shell shares have gained +51.3% over the past three months against the Zacks International Integrated Oil industry's rise of +33.8%. The Zacks analyst believes that Europe's largest oil company hasn't been immune to the coronavirus-induced energy downturn and is also facing some headwinds on the production front.
There are also worries over the company's poor reserve replacement ratio of just 76%. Hence, the stock warrants a cautious stance. Meanwhile, Royal Dutch Shell's trading business was instrumental in helping the supermajor partly cushion the impact of oil price slump.
In particular, the Anglo-Dutch multinational company's position as a key supplier of liquefied natural gas should benefit its long-term cash flow growth on the back of attractive growth opportunities. It is also making solid progress toward the transition to a renewable energy-focused future.
) read the full research report on Royal Dutch Shell here >>>
Other noteworthy reports we are featuring today include Gilead Sciences and FedEx.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.